Three TPO-RAs, romiplostim, eltrombopag and avatrombopag, have been assessed and recommended as second-line options for primary ITP by the National Institute for Health and Care Excellence (NICE). The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.